Artivion, Inc. $AORT Shares Sold by GW&K Investment Management LLC

GW&K Investment Management LLC trimmed its position in Artivion, Inc. (NYSE:AORT) by 10.7% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 753,752 shares of the company’s stock after selling 90,155 shares during the period. GW&K Investment Management LLC’s holdings in Artivion were worth $34,379,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Cerity Partners LLC lifted its position in Artivion by 28.2% in the fourth quarter. Cerity Partners LLC now owns 6,210 shares of the company’s stock worth $283,000 after purchasing an additional 1,366 shares during the period. O Shaughnessy Asset Management LLC lifted its position in Artivion by 34.0% in the fourth quarter. O Shaughnessy Asset Management LLC now owns 7,622 shares of the company’s stock worth $348,000 after purchasing an additional 1,935 shares during the period. Los Angeles Capital Management LLC acquired a new stake in Artivion in the fourth quarter worth approximately $446,000. State of Wyoming lifted its position in Artivion by 161.0% in the fourth quarter. State of Wyoming now owns 4,940 shares of the company’s stock worth $225,000 after purchasing an additional 3,047 shares during the period. Finally, Goldman Sachs Group Inc. lifted its position in Artivion by 144.4% in the fourth quarter. Goldman Sachs Group Inc. now owns 537,375 shares of the company’s stock worth $24,510,000 after purchasing an additional 317,518 shares during the period. 86.37% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. Needham & Company LLC cut their target price on Artivion from $58.00 to $44.00 and set a “buy” rating for the company in a research report on Friday, May 8th. Weiss Ratings downgraded Artivion from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday. Canaccord Genuity Group cut their price objective on Artivion from $51.00 to $48.00 and set a “buy” rating for the company in a research report on Friday, February 13th. Stifel Nicolaus set a $45.00 price objective on Artivion in a research report on Monday, June 1st. Finally, Wall Street Zen downgraded Artivion from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Seven analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $46.17.

Artivion Price Performance

AORT opened at $20.48 on Thursday. The stock has a fifty day moving average of $29.52 and a 200-day moving average of $37.33. The firm has a market capitalization of $994.29 million, a P/E ratio of 85.35 and a beta of 1.26. Artivion, Inc. has a 12-month low of $19.16 and a 12-month high of $48.25. The company has a quick ratio of 2.80, a current ratio of 3.86 and a debt-to-equity ratio of 0.48.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.